Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and outcome of children, adolescents and young adults participating in phase I/II clinical oncology trials: a 9-year center experience.
Pujol Manresa A, Buendía López S, Andión M, Herrero B, Lassaletta Á, Ramirez M, Ruano D, Hernández-Marqués C, Varo A, de Rojas T, Cortés Hernández M, Verdú-Amorós J, Martín Prado S, Artigas A, Redondo E, Ruiz Pato J, Herreros López P, Sevilla J, Madero L, Moreno L, Bautista Sirvent F, Rubio-San-Simón A. Pujol Manresa A, et al. Among authors: varo a. Front Pediatr. 2024 Sep 4;12:1423484. doi: 10.3389/fped.2024.1423484. eCollection 2024. Front Pediatr. 2024. PMID: 39318620 Free PMC article.
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD. Moreno L, et al. Among authors: varo a. Pediatr Blood Cancer. 2017 Jan;64(1):25-31. doi: 10.1002/pbc.26192. Epub 2016 Aug 24. Pediatr Blood Cancer. 2017. PMID: 27555472
Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers.
Cañete A, Peris-Bonet R, Capocaccia R, Pardo-Romaguera E, Segura V, Muñoz-López A, Fernández-Teijeiro A, Galceran-Padros J, Gatta G; Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG). Cañete A, et al. Cancer Epidemiol. 2022 Jun;78:102145. doi: 10.1016/j.canep.2022.102145. Epub 2022 Mar 25. Cancer Epidemiol. 2022. PMID: 35344745 Free article.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Mora J, Climent A, Roldán M, Flores MC, Varo A, Perez-Jaume S, Jou C, Celma MS, Lazaro JJ, Cheung I, Castañeda A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP, Cheung NK. Mora J, et al. Among authors: varo a. Front Oncol. 2024 May 15;14:1380917. doi: 10.3389/fonc.2024.1380917. eCollection 2024. Front Oncol. 2024. PMID: 38812778 Free PMC article.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Muñoz JP, et al. Among authors: varo a. Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J, Castañeda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M, Muñoz JP, Garraus M, Larrosa C, Salvador N, Lavarino C, Krauel L, Mañe S. Mora J, et al. Among authors: varo a. Cancers (Basel). 2023 Apr 28;15(9):2535. doi: 10.3390/cancers15092535. Cancers (Basel). 2023. PMID: 37174002 Free PMC article.
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
Castañeda A, Gorostegui M, Miralles SL, Chamizo A, Patiño SC, Flores MA, Garraus M, Lazaro JJ, Santa-Maria V, Varo A, Muñoz JP, Mora J. Castañeda A, et al. Among authors: varo a. ESMO Open. 2022 Apr;7(2):100462. doi: 10.1016/j.esmoop.2022.100462. Epub 2022 Apr 6. ESMO Open. 2022. PMID: 35397431 Free PMC article. Review.
Corrigendum to "How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain": [ESMO Open, 7 (2022) 100462].
Castañeda A, Gorostegui M, Miralles SL, Chamizo A, Patiño SC, Flores MA, Garraus M, Lazaro JJ, Santa-Maria V, Varo A, Muñoz JP, Mora J. Castañeda A, et al. Among authors: varo a. ESMO Open. 2022 Jun;7(3):100504. doi: 10.1016/j.esmoop.2022.100504. Epub 2022 May 26. ESMO Open. 2022. PMID: 35644100 Free PMC article. No abstract available.
21 results